Showing 10 RESULTS FOR
Alzheimer's Disease
What Matters Most? New Research Identifies Treatment Needs and Priorities of the Alzheimer’s Community
Lundbeck’s Ann Hartry, VP of US and Global Value Evidence, discusses the findings and insights from a first-of-its-kind Alzheimer’s research project.
Welcome to the New Era of Alzheimer’s Research: How People with Alzheimer’s and Care Partners are Shaping the Future of Drug Development
Learn how John and Leigh, who live with Alzheimer’s, are partnering with Lundbeck and AD PACE to inject patient needs, preferences into R&D.
Inside Job: Fighting Alzheimer’s Disease with Your Own Immune System
Learn more about new avenues in Alzheimer's research, including how activating a person's own immune system could modify the disease processes.
Stronger Together: Why Collaboration is Critical to Advancing Alzheimer’s Research
By Peter Anastasiou
Lundbeck’s executive vice president and head of North America discusses our collaborative approach to Alzheimer’s research.
Report Offers Hope, Outlines 537 New Drugs in Development for Neurological Disorders
A new report shows there are 537 medicines in development for neurological disorders, such as Parkinson's disease and Alzheimer's disease. Learn how Lundbeck is advancing treatments for brain disorders.